These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30084057)

  • 41. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
    Kondili LA; Gaeta GB; Brunetto MR; Di Leo A; Iannone A; Santantonio TA; Giammario A; Raimondo G; Filomia R; Coppola C; Amoruso DC; Blanc P; Del Pin B; Chemello L; Cavalletto L; Morisco F; Donnarumma L; Rumi MG; Gasbarrini A; Siciliano M; Massari M; Corsini R; Coco B; Madonia S; Cannizzaro M; Zignego AL; Monti M; Russo FP; Zanetto A; Persico M; Masarone M; Villa E; Bernabucci V; Taliani G; Biliotti E; Chessa L; Pasetto MC; Andreone P; Margotti M; Brancaccio G; Ieluzzi D; Borgia G; Zappulo E; Calvaruso V; Petta S; Falzano L; Quaranta MG; Weimer LE; Rosato S; Vella S; Giannini EG
    PLoS One; 2017; 12(10):e0185728. PubMed ID: 28977040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy.
    Caudai C; Materazzi A; Saladini F; Di Giambenedetto S; Torti C; Ricciardi B; Rossetti B; Almi P; De Luca A; Zazzi M
    Clin Microbiol Infect; 2018 Mar; 24(3):308.e5-308.e8. PubMed ID: 28811242
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Template-dependent multiple displacement amplification for profiling human circulating RNA.
    Wang W; Ren Y; Lu Y; Xu Y; Crosby SD; Di Bisceglie AM; Fan X
    Biotechniques; 2017 Jul; 63(1):21-27. PubMed ID: 28701144
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
    Bourlière M; Gordon SC; Flamm SL; Cooper CL; Ramji A; Tong M; Ravendhran N; Vierling JM; Tran TT; Pianko S; Bansal MB; de Lédinghen V; Hyland RH; Stamm LM; Dvory-Sobol H; Svarovskaia E; Zhang J; Huang KC; Subramanian GM; Brainard DM; McHutchison JG; Verna EC; Buggisch P; Landis CS; Younes ZH; Curry MP; Strasser SI; Schiff ER; Reddy KR; Manns MP; Kowdley KV; Zeuzem S;
    N Engl J Med; 2017 Jun; 376(22):2134-2146. PubMed ID: 28564569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.
    Coppola N; De Pascalis S; Messina V; Di Caprio G; Martini S; de Stefano G; Starace M; Stornaiuolo G; Stanzione M; Ascione T; Minichini C; Sangiovanni V; Zampino R; Calò F; Rinaldi L; Persico M; Federico A; Buonomo AR; Borgia G; Gaeta GB; Filippini P; Gentile I
    Antivir Ther; 2017; 22(7):551-558. PubMed ID: 28165327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
    Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
    Zeuzem S; Mizokami M; Pianko S; Mangia A; Han KH; Martin R; Svarovskaia E; Dvory-Sobol H; Doehle B; Hedskog C; Yun C; Brainard DM; Knox S; McHutchison JG; Miller MD; Mo H; Chuang WL; Jacobson I; Dore GJ; Sulkowski M
    J Hepatol; 2017 May; 66(5):910-918. PubMed ID: 28108232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
    Di Maio VC; Cento V; Lenci I; Aragri M; Rossi P; Barbaliscia S; Melis M; Verucchi G; Magni CF; Teti E; Bertoli A; Antonucci F; Bellocchi MC; Micheli V; Masetti C; Landonio S; Francioso S; Santopaolo F; Pellicelli AM; Calvaruso V; Gianserra L; Siciliano M; Romagnoli D; Cozzolongo R; Grieco A; Vecchiet J; Morisco F; Merli M; Brancaccio G; Di Biagio A; Loggi E; Mastroianni CM; Pace Palitti V; Tarquini P; Puoti M; Taliani G; Sarmati L; Picciotto A; Vullo V; Caporaso N; Paoloni M; Pasquazzi C; Rizzardini G; Parruti G; Craxì A; Babudieri S; Andreoni M; Angelico M; Perno CF; Ceccherini-Silberstein F;
    Liver Int; 2017 Apr; 37(4):514-528. PubMed ID: 28105744
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
    Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus.
    Wei B; Kang J; Kibukawa M; Chen L; Qiu P; Lahser F; Marton M; Levitan D
    J Mol Diagn; 2016 Sep; 18(5):643-656. PubMed ID: 27393904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. From current status to optimization of HCV treatment: Recommendations from an expert panel.
    Craxì A; Perno CF; Viganò M; Ceccherini-Silberstein F; Petta S;
    Dig Liver Dis; 2016 Sep; 48(9):995-1005. PubMed ID: 27388261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study.
    Salerno F; Borzio M; Pedicino C; Simonetti R; Rossini A; Boccia S; Cacciola I; Burroughs AK; Manini MA; La Mura V; Angeli P; Bernardi M; Dalla Gasperina D; Dionigi E; Dibenedetto C; Arghittu M;
    Liver Int; 2017 Jan; 37(1):71-79. PubMed ID: 27364035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.
    Lawitz EJ; Dvory-Sobol H; Doehle BP; Worth AS; McNally J; Brainard DM; Link JO; Miller MD; Mo H
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5368-78. PubMed ID: 27353271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
    Abergel A; Metivier S; Samuel D; Jiang D; Kersey K; Pang PS; Svarovskaia E; Knox SJ; Loustaud-Ratti V; Asselah T
    Hepatology; 2016 Oct; 64(4):1049-56. PubMed ID: 27351341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
    Sarrazin C; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Pang PS; Chuang SM; Ma J; Ding X; Afdhal NH; Kowdley KV; Gane EJ; Lawitz E; Brainard DM; McHutchison JG; Miller MD; Mo H
    Gastroenterology; 2016 Sep; 151(3):501-512.e1. PubMed ID: 27296509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
    Gane EJ; Schwabe C; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CA
    Gastroenterology; 2016 Sep; 151(3):448-456.e1. PubMed ID: 27240903
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
    Iio E; Shimada N; Abe H; Atsukawa M; Yoshizawa K; Takaguchi K; Eguchi Y; Nomura H; Kuramitsu T; Kang JH; Matsui T; Hirashima N; Tsubota A; Kusakabe A; Hasegawa I; Miyaki T; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
    J Gastroenterol; 2017 Jan; 52(1):94-103. PubMed ID: 27236547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin.
    Fevery B; Thys K; Van Eygen V; Verbinnen T; Van Rossem E; Buelens A; Aerssens J; Witek J; Picchio G; De Meyer S; Lenz O
    Open Forum Infect Dis; 2016 Mar; 3(2):ofw052. PubMed ID: 27186579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.
    Pawlotsky JM
    Gastroenterology; 2016 Jul; 151(1):70-86. PubMed ID: 27080301
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
    Serre SB; Jensen SB; Ghanem L; Humes DG; Ramirez S; Li YP; Krarup H; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3563-78. PubMed ID: 27021330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.